Here are seven insights:
1. The study included 335 patients.
2. All patients received ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks.
3. Overall, 322 patients — 96 percent — had a sustained virologic response at 12 weeks after the end of therapy.
4. Rates of sustained virologic response were similar regardless of previous treatment or the presence of cirrhosis.
5. Of the 13 patients who did not have a sustained virologic response, 10 had a relapse after the end of treatment.
6. The most common adverse events were headache (25 percent), fatigue (21 percent) and diarrhea (11 percent).
7. No patient discontinued treatment because of adverse events.
More articles on GI/endoscopy:
20 GI/endoscopy company updates for the 1st half of 2015
GI physician compensation: 13 statistics
6 GI physicians in the news – July 24, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
